# Sara M. Tolaney

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sara-m-tolaney/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,942 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 86 |
| i10-index | 362 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5069056507 |
| ORCID iD | https://orcid.org/0000-0002-5940-8671 |
| Works | 1,340 |

## Researcher papers

- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)](https://scholariq.org/papers/impact-of-the-addition-of-carboplatin-and-or-bevacizumab-to-neoadjuvant-once-per/)
- [BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer](https://scholariq.org/papers/braf-mutation-predicts-a-poorer-clinical-prognosis-for-papillary-thyroid-cancer/)
- [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-hziy-in-refractory-metastatic-triple-negative-breast/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study](https://scholariq.org/papers/adjuvant-abemaciclib-combined-with-endocrine-therapy-for-high-risk-early-breast/)
- [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://scholariq.org/papers/biomarker-analyses-in-the-phase-iii-ascent-study-of-sacituzumab-govitecan-versus/)
- [Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/abemaciclib-plus-trastuzumab-with-or-without-fulvestrant-versus-trastuzumab-plus/)
- [A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer](https://scholariq.org/papers/a-phase-ii-study-of-abemaciclib-in-patients-with-brain-metastases-secondary-to/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.